Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead

Journal of Controlled Release

Volumn 146, Issue 2, 2010, Pages 175-181

  Moghimi, S M ^a   Andersen, A J ^a   Hashemi, S H ^a   Lettiero, B ^a   Ahmadvand, D ^a   Hunter, A C ^b   Andresen, T L ^c   Hamad, I ^d   Szebeni, J ^e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d APPLIED SCIENCE PRIVATE UNIVERSITY   (Jordan)

^e SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Carbon nanotube; Complement activation; Liposome; Micelle; Poly(ethylene glycol); Pseudoallergy

Indexed keywords

ALIPHATIC COMPOUNDS; CHEMICAL ACTIVATION; ETHYLENE GLYCOL; LIPOSOMES; MICELLES; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; POLYOLS;

COMPLEMENT ACTIVATIONS; CONTROLLED DELIVERY; DELIVERY SYSTEMS; EXPERIMENTAL ANIMALS; HYPERSENSITIVITY REACTION; PROTEIN ADSORPTION; PSEUDOALLERGY; RATE LIMITING FACTORS;

CARBON NANOTUBES;

CARBON NANOTUBE; DOXORUBICIN; MACROGOL; PHOSPHOLIPID;

ARTICLE; COMPLEMENT ACTIVATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; NANOENGINEERING; NANOMEDICINE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; ST SEGMENT DEPRESSION; TACHYCARDIA;

EID: 77955415384     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.04.003     Document Type: Article

References (48)

1. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
2. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J. 2005, 19:311-330.
3. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
4. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
5. Moghimi S.M., Kissel T. Particulate nanomedicines. Adv. Drug Deliv. Rev. 2006, 58:1451-1455.
6. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 2006, 58:1532-1555.
7. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Rel. 2001, 73:137-172.
8. Liu F., Liu D. Long-circulating emulsions (oil-in-water) as carriers of lipophilic drugs. Pharm. Res. 1995, 12:1060-1064.
9. Liu Z., Davis C., Cai W., He L., Chen X., Dai H. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:1410-1415.
10. Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F.M., Gabizon A. Liposomal doxorubicin: activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995, 13:1777-1785.
11. Alberts D.S., Garcia D.J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997, 54:30-45. Suppl.
12. Channan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., Muggia F.M. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Annal. Oncology 2003, 14:1430-1437.
13. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005, 216:106-121.
14. Szebeni J., Baranyi L., Savay S., Bodo M., Milosevits J., Alving C.R., Bunger R. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol. Heart Cir. Physiol. 2006, 290:H1050-H1058.
15. Moghimi S.M., Hamad I. Liposome-mediated triggering of complement cascade. J. Liposome Res. 2008, 18:195-209.
16. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42:463-478.
17. Szebeni J., Moghimi S.M. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. J. Liposome. Res. 2009, 19:85-90.
18. Hamad I., Hunter A.C., Szebeni J., Moghimi S.M. poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 2008, 46:225-232.
19. Lustig R., McIntosh-Lowe N., Rose C., Haas J., Kransnow S., Spaulding M., Prosnitz L. Phase I/II study of Fluosol-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell tumours of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 1989, 16:1587-1593.
20. Moghimi S.M., Hunter A.C., Dadswell C.M., Savay S., Alving C.R., Szebeni J. Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim. Biophys. Acta 2004, 1689:103-113.
21. Marone G., Bova M., Detoraki A., Onorati A.M., Rossi F.W., Spadaro G. The human heart as a shock organ in anaphylaxis. Novartis Found. Symp. 2004, 257:133-149.
22. Marone G., Patella V., de Crescenzo G., Genovese A., Adt M. Human heart mast cells in anaphyaxis and cardiovascular disease. Int. Arch. Allergy Immunol. 1995, 107:72-75.
23. Markiewski M.M., Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. Complement and coagulation: strangers or partners in crime?. Trend. Immunol. 2007, 28:184-192.
24. Andersen A.J., Hashemi A.H., Andresen T.L., Hunter A.C., Moghimi S.M. Complement: alive and kicking nanomedicines. J. Biomed. Nanotechnol. 2009, 5:364-372.
25. Szebeni J., Baranyi L., Savay S., Lutz H.U., Jelezarova E., Bunger R., Alving C.R. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil). J. Liposome Res. 2000, 10:469-481.
26. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman HJ H.J., Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110:103-111.
27. Richter A.W., Akerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int. Arch. Allergy Appl. Immunol. 1984, 70:124-131.
28. Ludge A., McClintock K., Phelps J.R., MacLachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 2006, 13:328-337.
29. Ishida T., Kashima S., Kiwada H. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J. Control. Rel. 2008, 126:162-165.
30. Crupi V., Jannelli M.P., Magazu S., Maisano G., Majolino D., Migliardo P., Pontiero R. Raman spectroscopic study of water in the poly(ethylene glycol) hydration shell. J. Mol. Struct. 1996, 381:207-212.
31. Kozielski M. Conformational changes in the chains of polyoxyethyleneglycols. J. Mol. Liquid 2006, 128:105-107.
32. Moghimi S.M., Hamad I., Andresen T.L., Jørgensen K., Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 2006, 20:2591-2593.
33. Laverty P.H., Leskovar A., Breur G.J., Coates J.R., Bergman R.L., Widmer W.R., Toombs T.J., Shapiro S., Borgens R.B. A preliminary study of intravenous surfactants in paraplegic dogs: polymer therapy in canine clinical SCI. J. Neurotrauma 2004, 21:1767-1777.
34. Koob A.O., Borgens R.B. Polyethylene glycol treatment after traumatic brain injury reduces β-amyloid precursor protein accumulation in degenerating axons. J. Neurosci. Res. 2006, 83:1558-1563.
35. Moghimi S.M., Hunter A.C. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm. Res. 2001, 18:1-8.
36. Kostarelos K., Bianco A., Prato M. promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat. Nanotechnol. 2009, 4:627-633.
37. Salvador-Morales C., Flahaut E., Sim E., Sloan J., Green M.L., Sim R.B. Complement activation and protein adsorption by carbon nanotubes. Mol. Immunol. 1996, 43:193-201.
38. Salvador-Morales C., Basiuk E.V., Basiuk V.A., Green M.L.H., Sim R.B. Effects of covalent functionalization on the biocompatibility characteristics of multi-walled carbon nanotubes. J. Nanosci. Nanotechnol. 2008, 8:2347-2356.
39. Hamad I., Hunter A.C., Rutt K.J., Liu Z., Dai H., Moghimi S.M. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol. Immunol. 2008, 45:3797-3803.
40. Pantarotto D., Partidos C.D., Hoebeke J., Brown F., Kramer E., Briand J.P., Muller S., Prato M., Bianco A. Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem. Biol. 2003, 10:961-966.
41. Fearon D.T., Carroll M.C. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Ann. Rev. Immunol. 2000, 18:393-422.
42. Markiewski M.M., De Angelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., Coukos G., Lambris J.D. Modulation of the antitumor immune response by complement. Nat. Immunol. 2008, 9:1225-1235.
43. Moghimi S.M., Andresen T.L. Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines. Mol. Immunol. 2009, 46:1571-1572.
44. Hunter A.C. Application of quartz crystal microbalance to nanomedicine. J. Biomed. Nanotechnol. 2009, 5:669-675.
45. Hersam M.C. Progress towards monodisperse single-walled carbon nanotubes. Nat. Nanotechnol. 2008, 3:387-394.
46. Salvador-Morales C., Towensend P., Flahaut E., Venien-Bryan C., Vlandas A., Green M.L.H., Sim R.B. Binding of pulmonary surfactant proteins to carbon nanotubes; potential for damage to lung immune defense mechanisms. Carbon 2007, 45:607-617.
47. Mitchell L.A., Lauer F.T., Burchiel S.W., McDonald J.D. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat. Nanotechnol. 2009, 4:451-456.
48. Poland C.A., Duffin R., Kinloch I., Maynard A., Wallace W.A.H., Seaton A., Stone V., Brown S., MacNee W., Donaldson K. Carbon nanotubes introduced into the abdominal cavity of mice shows asbestos-like pathogenicity in a pilot study. Nat. Nanotechnol. 2008, 3:423-428.